invivodata

invivodata consults on ClinRO instrument for UCB

Friday, May 11, 2012 12:19 PM

Pittsburgh, Penn.-based invivodata, a fully-integrated clinical outcomes assessments company, has been chosen to deliver regulatory consulting services for a phase III trial that UCB is conducting in the development of a unique biopharmaceutical product to treat Rheumatoid Arthritis (RA).

More... »


DiaryPRO helps Insys Therapeutics with data efficacy

Wednesday, February 15, 2012 03:28 PM

DiaryPRO, invivodata’s field-based electronic COA solution, captured the primary efficacy data in the pivotal studies that led to Insys Therapeutics’ successful New Drug Application (NDA) for Subsys (fentanyl sublingual spray).

More... »


Dr. Saul Shiffman recognized by Carnegie awards

Tuesday, February 7, 2012 03:04 PM

Dr. Saul Shiffman, co-founder and chief science officer of invivodata, received an honorable mention in the entrepreneur category of the 2012 Carnegie Science Awards, which recognizes outstanding science and technology achievements in western Pennsylvania.

More... »

INC Research Provides ePRO Services Through Invivodata Partnership

Friday, March 12, 2010 06:34 AM

Raleigh, N.C.-based CRO  INC Research added electronic patient reported outcomes (ePRO) services to its offerings through a partnership with ePRO provider invivodata. Prior to the formation of the strategic partnership, the two companies collaborated on multiple international clinical trials.

More... »

Top Stories for the Week of Sept. 18th 2006

Wednesday, September 20, 2006 10:35 AM

Top News

More... »


CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks worldwide toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs